Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Schaberl-Moser, R.
metastatic colorectal cancer-focus on precision oncology
MEMO-MAG EUR MED ONC. 2025; Doi: 10.1007/s12254-025-01075-y
Web of Science FullText FullText_MUG

Leading authors Med Uni Graz: Schaberl-Moser Renate
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Precision oncology has changed first-line therapy in metastatic colorectal cancer (mCRC) considerably. During ASCO 2025, relevant practice-changing data were reported for distinct molecular subgroups. Key trials addressed novel approaches in upfront therapy of BRAF(V600E) mutated (BREAKWATER) and dMMR/MSI-h mCRC. In comparison with standard of care (SOC), BRAF(V600E) inhibition demonstrated a doubling of overall survival (OS). An update of the CheckMate 8HW trial confirmed the plateauing of OS curves after longer follow-up, suggesting the potential for cure with dual immune blockade in MSI-h mCRC. Targeting the KRAS(G12C) mutation is also a promising strategy; data were presented for sotorasib plus panitumumab plus FOLFIRI in pretreated patients. Although the numbers are small, the results on objective response rate (ORR), progression-free survival (PFS), and OS are clinically meaningful. Consequently, KRAS(G12C) inhibition is now evaluated in a first-line setting (CodeBreaK 301). Additionally, phase 1/2 data for next-generation KRAS(G12C) inhibitors were presented. Immune therapy as part of therapeutic strategies in pMMR/MSS tumors remains a topic of special interest. The results of an interim analysis from early phase 1/2 dose finding and dose expansion trials were reported. The aim of this review is to summarize clinically relevant abstracts, focusing on practice-changing trials, and to provide insights into new therapeutic strategies.
Find related publications in this database (Keywords): Targeted therapy; Immune therapy; Targeted therapy; BRAF(V600E) muation; dMMR/MSI-h; KRAS(G12C) mutation